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Abstract 
Solid lipid nanoparticle (SLNs) formulae were utilized for the release of 5-flurouracil (5-FU) 
i n s i d e   t h e   c ol o n i c   m e d i u m   f o r   l o c a l   t r e a t m e n t   o f   c o l o n   c a n c e r .   S L N s   w e r e   p r e p a r e d   b y   d o u b l e  
emulsion-solvent evaporation technique (w/o/w) using triglyceride esters, Dynasan 114 or 
Dynasan™ 118 along with soyalecithin as the lipid parts. Different formulation parameters; 
including type of Dynasan, soyalicithin:Dynasan ratio, drug:total lipid ratio, and polyvinyl al-
cohol (PVA) concentration were studied with respect to particle size and drug entrapment 
e f f i c i e n c y .   R e s u l t s   s h o w e d   t h a t   f o r m u l a   8   ( F 8 )   w i t h   c o m p o s i t i o n   o f   2 0 %   5 -FU, 27% Dynasan™ 
114, and 53% soyalithicin and F14 (20% 5-FU, 27% Dynasan™ 118, and 53% soyalithicin), 
w h i c h   w e r e   s t a b i l i z e d   b y   0 . 5 %   P V A ,   a s   w e l l   a s   F 1 0   w i t h similar composition as F8 but stabilized 
b y   2 %   P V A   w e r e   c o n s i d e r e d   t h e   o p t i m u m   f o r m u l a e   a s   t h e y   c o m b i n e d   s m a l l   p a r t i c l e   s i z e s   a n d  
relatively high encapsulation efficiencies. F8 had a particle size of 402.5 nm ± 34.5 with a 
polydispersity value of 0.005 and an encapsulation efficiency of 51%, F10 had a 617.3 nm ± 54.3 
particle size with 0.005 polydispersity value and 49.1% encapsulation efficiency, whereas 
formula F14 showed a particle size of 343 nm ± 29 with 0.005 polydispersity, and an en-
capsulation effi c i e n c y   o f   5 9 . 0 9 % .   D S C   a n d   F T I R   r e s u l t s   s u g g e s t e d   t h e   e x i s t e n c e   o f   t h e   l i p i d s   i n  
the solid crystalline state. Incomplete biphasic prolonged release profile of the drug from The 
t h r e e   f o r m u l a e   w a s   o b s e r v e d   i n   p h o s p h a t e   b u f f e r   p H   6 . 8   a s   w e l l   a s   s i m u l a t e d   c o l onic medium 
containing rat caecal contents. A burst release with magnitudes of 26%, 32% and 28.8% cu-
mulative drug released were noticed in the first hour samples incubated in phosphate buffer 
pH 6.8 for both F8, F10 and F14, respectively, followed by a slow release profile reaching 50%, 
46.3% and 52% after 48 hours. 
Key words: Solid lipid nanoparticles, double emulsion, colon cancer; Dynasan, 5-flurouraci, poly-
vinyl alcohol 
Introduction 
C o l o r e c t a l   c a n c e r   i s   t h e   s e c o n d   l e a d i n g   c a u s e   o f  
cancer-r e l a t e d   d e a t h   f o r   m e n   a n d   w o m e n   w o r l d w i d e .  
E a c h   y e a r   t h e r e   a r e   a b o u t   o n e   m i l l i o n   n e w   c a s e s   o f  
c o l o r e c t a l   c a n c e r .   I t s   i n c i d e n c e   h a s   i n c r e a s e d   o v e r   t h e  
last 25 years [1]. Colorectal cancer is a disease that is 
m a n i f e s t e d   b y   t h e   f o r m a t i o n   o f   a d e n o m a t o u s   p o l y p s  
a n d   m a l i g n a n t   c e l l s   i n   t h e   c o l o n   [ 2 ] .   T h e s e   a b n o r m a l  
cells creating tumors are characterized by unregulated 
replication and the capability of spreading to other 




for the local delivery of a high concentration of active 
agents in the colon to improve pharmacotherapy and 
reduce its potential systemic toxicity and side effects 
[3].  The  early  detection,  diagnosis,  a n d   t h e   u s e   o f  
more  effective  and  less   t o x i c   s y s t e m s   w o u l d   t r e-
mendously improve the efficacy of therapy [1-3]. 
N a n o t e c h n o l o g y   h a s   b e c o m e   a   r a p i d l y   g r o w i n g  
field with potential applications in health and drug 
therapy  [4-6].  Nanoparticles  have  extraordinary 
physical and chemical properties resulting  from  the 
nanosize  effect  [7].  They  play  an  important  role  in 
c a n c e r   t h e r a p y   t o   d e t e c t   o r   t o   d e l i v e r   t h e   d r u g   t o   t h e  
cancerous cell without attacking the normal cells and 
h a v e   g o o d   a b i l i t y   t o   f o r m   a   c o m p l e x   w i t h   a   v a r i e t y   o f  
drugs through chemical bindings [8]. The phenome-
non of nanoparticles has been applied in a number of 
research  approaches  for  the  improvement  of  cancer 
therapeutics including liposomes [9], polymeric na-
noparticles [10], dendrimers [11], and metallic nano-
particles [12]. Generally, lipid-based nanoparticles are 
c o n s i d e r e d   t h e   l e a s t   t o x i c   a m o n g   a l l   t h e   o t h e r   n a n o-
particles for in vivo applications, in addition to the 
s i g n i f i c a n t   p r o g r e s s   t h a t   h a s   b e e n   achieved in the de-
livery  of  DNA/RNA  using  lipid-based  na-
no-assemblies [13]. 
Solid lipid n a n p a r t i c l e s   ( S L N s )   h a v e   b e e n   p r o-
posed as an alternative drug carrier system to other 
novel  delivery  approaches  such  as  emulsions, lipo-
somes,  and  polymeric  nanoparticles  due  to  various 
advantages, including feasibility of incorporation of 
lipophilic and hydrophilic drugs, improved physical 
s t a b i l i t y ,   l o w   c o s t ,   e a s e   o f   s c a l e -up, and manufactur-
i n g   [ 1 4 , 1 5 ] .   I n   c o n t r a s t   t o   e m u l s i o n s   a n d   l i p o s o m e s ,  
t h e   p a r t i c l e   m a t r i x   o f   S L N s   i s   c o m p o s e d   o f   s o l i d   l i-
p i d s .   T h e   m a j o r i t y   o f   l i p i d s   c o m m o n l y   u s e d   a r e   t r i g-
lyceride  este r s   o f   h y d r o g e n a t e d   f a t t y   a c i d s .   H y d r o-
genated  cottonseed  oil  (Lubritab™  or  Sterotex™), 
hydrogenated palm oil (Dynasan™ P60 or Softisan™ 
154), hydrogenated castor oil (Cutina™ HR), and hy-
drogenated  soybean  oil  (Sterotex™  HM,  or  Lipo™) 
are typical examples [16].  
General features of SLNs are their composition 
of  physiological  compounds,  possible  routes  of  ad-
ministration by intravenous, oral and topical, large 
s c a l e   p r o d u c t i o n   b y   h i g h   p r e s s u r e   h o m o g e n i z a t i o n ,  
a n d   t h e   r e l a t i v e l y   l o w   c o s t s   o f   e x c i p i e n t s   [ 1 6 -18]. A 
number of studies have recently been published about 
their  production  [19],  physicochemical  characteriza-
tion of particles [20], and drug incorporation and re-
lease  [21].  SLNs  carrying  anticancer  drugs  such  as 
doxorubicin and paclitaxel had previously been  de-
veloped and the antiprolifirative effect of SLNs versus 
conventional  drug  formulations  was  also  evaluated 
on HT-2 9   c e l l s .   I n   v i t r o   c y t o t o x i c i t y   o f   S L N s   c a r r y i n g  
anticancer drugs was higher than that of conventional 
drug formulations [22].  
5-FU is an anticancer agent and the most widely 
u s e d   d r u g   i n   t h e   t r e a t m e n t   o f   m a l i g n a n c i e s   a r i s i n g  
from breast, gastrointestinal tract, head, and neck re-
g i o n s   o f   t h e   b o d y   f o r   s e v e r a l   d e c a d e s   [ 2 3 ] .   I t   i s   c o n s i-
dered the major chemotherapeutic agent with clinical 
activity  against  colorectal  cancer  [24-27].  Localizing 
5-F U   d i r e c t l y   t o   t h e   c o l o n   i s  expected to reduce sys-
temic  side  effects  allowing  more  effective  and  safe 
therapy with higher tumor diffusivity [28]. 5-FU  was 
u s e d   i n   t h i s   s t u d y   a s   a   m o d e l   d r u g .   I m p r o v e m e n t   o f  
t i s s u e   d i s t r i b u t i o n   a n d   t a r g e t i n g   o f   d r u g s   b y   u s i n g  
S L N s   h a v e   b e e n   r e p o r t e d   f o r   s o m e   d r u g s   i n c l u d i n g  
anticancers [29].  
T h e   a i m   o f   t h i s   w o r k   w a s   t o   p r e p a r e   a n d   c h a-
racterize  5-FU  solid  lipid  nanparticles.  A  double 
emulsion-solvent evaporation (w/o/w) method was 
c h o s e n   a n d   w a s   o p t i m i z e d   t o   o b t a i n   S L N s   w i t h   l o w  
particle size and a relatively high encapsulation effi-
ciency as well as a consistent release profile in simu-
lated colonic medium.  
Materials and Methods 
5-FU w a s   o b t a i n e d   f r o m   S i g m a -Aldrich Chemi-
cal Company (St. Louis, MO, USA). Dynasan 114 
a n d   1 1 8   w e r e   a c q u i r e d   f r o m   S a s o l   G e r m a n y   G m b H  
(Witten, Germany). Soya lecithin 30% was purchased 
from  AppliChem  (Darmstadt,  Germany).  Polyvinyl 
alcohol (PVA), M.W. 22,000 was obtained from BDH 
Laboratories (Poole, England). All other reagents and 
chemicals were of analytical grade. 
Preparation of solid lipid nanoparticles 
Weighed amounts of soyalecithin and Dynasan 
were dissolved in 10 ml of dichloromethane. Certain 
amounts  of  5-F U   w a s   d i s s o l v e d   i n   4   m l   o f   2 . 5 %  w/v 
lactose monohydrate in distilled water to avoid par-
t i c l e   a g g r e g a t i o n   a f t e r   f r e e z e   d r y i n g   o f   S L N s .   B o t h  
lipid and aqueous solutions were mixed and emulsi-
fied by probe-sonication (Bandelin, Berlin, Germany) 
f o r   a n   o p t i m i z e d   p e r i o d   o f   t i m e   ( 3 × 1   m i n u t e s )   at 40% 
voltage  efficiency  in  an  ice  bath.  The  formed  w/o 
primary emulsion was immediately poured onto 40 
ml aqueous solution of PVA continuously stirred at 
1 0 0 0   r p m   o v e r   i c e   b a t h   f o r   3 0   m i n u t e s .   T h e n ,   t h e  
temperature was increased gradually (15-18 °C)  dur-
ing stirring and subjected to solvent evaporation for 
another  30  minutes.  Lipid  nanoparticles  were  sepa-
rated  from  bulk  aqueous  phase  by  centrifugation  at 
1 4 0 0 0   r p m   f o r   3 0   m i n   ( H e t t i c h ,   M I K R O -120, Tuttlin-
g e n ,   G e r m a n y ) .   A f t e r   s u b s e q u e n t   w a s h i n g   w i t h   c o l d  
disti l l e d   w a t e r ,   t h e   r e s i d u e   w a s   d i s p e r s e d   i n   t r i s -HCl 




LD  freeze-drier,  Osterode,  Germany).  Table  1, 
r e p r e s e n t s   t h e   e x a c t   c o m p o s i t i o n   o f   e a c h   o f   t h e   p r e-
p a r e d   f o r m u l a .   T h e   e f f e c t   o f   d i f f e r e n t   f o r m u l a t i o n  
parameters,  such  as  type  of  Dynasan,  soyalici-
thin:Dynasan ratio, drug:total lipid ratio, and the PVA 
concentration  on  the  particle  size  and  drug  entrap-
ment efficiency were investigated. 
 
Table 1. Composition of each of the prepared formulae 
Formulations  % w/w  % PVA 
Soyalicithin  Dynasan  5-FU 
F1  26  52a  22  1 
F2  52  26  22  1 
F3  78  0  22  1 
F4  52  27  20  1 
F5  26  52  22  0.5 
F6  52  26  22  0.5 
F7  39  39  22  0.5 
F8  53  27  20  0.5 
F9  26  52  22  2 
F10  53  27  20  2 
F11  53  27  20  1 
F12  53  27  20  3 
F13  53  27b  20  0.5 
F14  53  27  20  0.5 
F15  53  27  20  0.5 
aD114 is Dynasan™ 114 
bD118 is Dynasan™ 118 
  
Measurement of particle size 
T h e   m e a n   s i z e   a n d   p o l y d i s p e r s i t y   i n d e x   o f   t h e  
size distribution for each formula were determined by 
photon correlation spectroscopy using 90 Plus particle 
size analyzer, Brookhaven Instruments Corporation 
(Holtsville, New York, USA). The SLNs dispersions 
were diluted 1:1000 with distilled water. Analysis was 
p e r f o r m e d   a t   2 5   ° C   w i t h   a n   a n g l e   o f   d e t e c t i o n   o f   9 0 ° .  
Each reported value is the average of three measure-
ments.  The  polydispersity  index  measures  the  size 
distribution of the nanoparticles population. 
Differential scanning calorimetry 
The  thermal  behavior  of  some  selected  SLN 
formulae  was  investigated  by  differential  scanning 
calorimetry  (DSC)  using  a  Shimadzu  DSC-60  (Shi-
m a d z u   C o r p o r a t i o n ,   T o k y o ,   J a p a n ) .   S a m p l e s   o f   4 -7   m g  
w e r e   w e i g h e d   a n d   a   h e a t i n g   r a t e   o f   1 0   º C / m i n   w a s  
employed in the range of 25 ºC to 350 ºC.  
Fourier transform infrared spectroscopy (FTIR) 
T h e   F T I R   s p e c t r a   o f   s a m p l e s  were recorded on 
the  o n   a   P e r k i n E l m e r   s p e c t r u m   B X   F T I R   ( P e r k i n E l-
m e r ,   W a l t h a m ,   M A ,   U S A )  u s i n g   t h e   p o t a s s i u m   b r o-
mide (KBr) disc technique. Samples equivalent to 2 
mg  of  5-F U   w e r e   m i x e d   w i t h   p o t a s s i u m   b r o m i d e  
(about 100 mg) in a clean glass pestle and mortar and 
were compressed t o   o b t a i n   a   p e l l e t .   B a s e l i n e   w a s   c o r-
r e c t e d   a n d   t h e   s a m p l e s   w e r e   s c a n n e d   a g a i n s t   a   b l a n k  
K B r   p e l l e t   b a c k g r o u n d   a t   a   w a v e   n u m b e r   r a n g i n g  
from 4000-400 cm-1 with a resolution of 1.0 cm-1.  
Determination of % entrapment efficiency and 
drug loading  
The  percentage  drug  entrapment  efficiency 
( % E E )   a n d   %   d r u g   l o a d i n g   ( % D L )   o f   5 -FU  in  SLNs 
formulations  were  determined  by  centrifugation  of 
the colloidal samples at 14000 rpm at 25 °C for 30 min. 
The non-entrapped 5-FU amounts in the supernatant 
obtained  after  centrifugation  of  nanoparticles  were 
determined by UV spectroscopy at 266 nm. 
T h e   % EE of 5-FU entrapped within nanoparticles 
was calculated by dividing the difference between the 
total  amount  used  (Wtotal  5-FU)   a n d   t h e   f r e e   a m o u n t  
presented in the aqueous phase of supernatant (Wfree 
5-FU)   b y   t h e   t o t a l   a m o u n t   u s e d   o f   5 -FU. The %DL was 
o b t a i n e d   b y   d i v i d i n g   t h a t   d i f f e r e n c e   b y   t h e   t o t a l  
weight of SLNs according to the following formulae: 
 
 
Scanning electron microscopic (SEM) analysis 
The morphology characteristics of the prepared 
SLNs  were  examined  under  the  scanning  electron 
microscope (JSM-6360LV Scanning Microscope; Jeol, 
Tokyo,  Japan).  Before  microscopy,  SLNs  produced 
from F14 were suspended in a phosphate buffer (pH 
7 )   b y   v o r t e x   f o r   1   m i n u t e ,   a n d   t h e n   o n e   d r o p   w a s  
s p r e a d   o n   a   s m a l l   c l e a n   s l i d e   c o v e r   a n d   l e f t   t o   d r y  
o v e r n i g h t   i n   a   d e s i c a t o r .   I n   t h e   n e x t   d a y ,   t h e y   w e r e  
mounted on carbon tape and sputter-coated using a 
thin gold palladium layer under an argon atmosphere 
using a gold sputter module in a high-vacuum eva-
porator (JFC-1 1 0 0   f i n e   c o a t   i o n   s p u t t e r ;   J e o l ,   T o k y o ,  
Japan).  The  coated  samples  were  then  scanned  and 
photomicrographs were taken at an acceleration vol-
tage of 20 kV. 
In vitro release study 
C e r t a i n   w e i g h t s   f r o m   e a c h   o f   t h e  selected  for-
m u l a   e q u i v a l e n t   t o   1   m g   5 -FU were immersed in 10 ml 
o f   p h o s p h a t e   b u f f e r   p H   6 . 8   i n   b i o l o g i c a l   s h a k e r   a t   3 7  
° C   a n d   8 0   r p m   s p e e d .   A l i q u o t s   o f   1  ml were with-




e q u a l   v o l u m e   o f   f r e s h   b u f f e r .   After centrifugation, the 
amount  of  drug  released  was  determined  spectro-
photometrically by measuring the absorbance of each 
aliquot supernatant at 266 nm.  
Drug release in medium containing rat caecal 
contents 
The drug release was assessed using a procedure 
intro d u c e d   b y   Y a s s i n   e t   a l .   ( 2 0 1 0 )   [ 3 0 ] .   B r i e f l y ,   m a l e  
r a t s   o f   m i x e d   b r e e d s   w e i g h i n g   2 0 0 -300  g  were  used 
throughout  this  study.  The  rats  were  euthanized 
while  under  ether  anesthesia  and  the  caecum  was 
exteriorized,  legated  at  the  two-ends  and  was 
cut-l o o s e .   T h e   c o n t e n t s   o f   t h e   f o r m e d   c a e c a l   b a g s   w e r e  
individually  weighed,  pooled,  and  suspended  in  a 
chilled phosphate b u f f e r   s a l i n e   ( p H   6 . 8 )   t o   g i v e   a   f i n a l  
d i l u t i o n   o f   3 %   ( w / v ) .   W e i g h t s   e q u i v a l e n t   t o   1   m g  
5-F U   f r o m   F 8 ,   F 1 0   a n d   F 1 4   w e r e   i n c u b a t e d   i n   2 0   m l   o f  
the suspension at 37 °C ± 0.5 and shaken at 80 rpm 
u s i n g   a   t h e r m o s t a t i c   s h a k i n g   w a t e r   b a t h .   T h e   e x p e r i-
ments were performed under nitrogen atmosphere to 
simulate anaerobic conditions. Aliquots (1 ml) sam-
ples were withdrawn, filtered, diluted, and analyzed 
using  HPLC at specified time intervals for 24 h. Re-
p l a c e m e n t   o f   s a m p l e s   w e r e   m a d e   b y   t h e   m e d i u m  
stored at the same temperature. 
Assay method 
A simple and sensitive stability-indicating HPLC 
m e t h o d   w i t h   a   U V   d e t e c t i o n   u s i n g   t h y m i n e   a s   a n   i n-
ternal standard was adopted [ 3 1 ] .   T h e   m e t h o d   w a s  
utilized for the assessment of stability of 5-F U   i n   r a t  
c a e c a l   c o n t e n t   a s   s i m u l a t e d   c o l o n   m e d i u m   u n d e r  
a n a e r o b i c   c o n d i t i o n s .   B r i e f l y ,   t h e   H P L C   s y s t e m   c o n-
sisted of a Waters Model 1515 HPLC pump, a Waters 
autosampler, Model  717  plus  (Waters Inc., Bedford, 
MA, USA), a Waters 2487 dual absorbance UV detec-
t o r   ( W a t e r s   I n c . ,   B e d f o r d ,   M A ,   U S A )   g o v e r n e d   b y   a  
microcomputer running Empower® software (version 
1154). The detector wavelength was set at 260 nm. 
Separation was achieved by isocratic elution with a 
m o b i l e   p h a s e   o f   4 0   m M   p h o s p h a t e   b u f f e r   a d j u s t e d   t o  
p H   7 . 0   u s i n g   1 0 %   w / v   p o t a s s i u m   h y d r o x i d e ,   d e l i-
vered at a flow-rate of 1.0 ml/min at ambient tem-
perature through a C18 analytical, µ-Bondapack col-
u m n   ( 1 5 0   m m   l e n g t h   ×   4 .   6   m m   i . d . ,   1 0   µ m   p a r ticle 
size). 
Statistical analysis 
T h e   s i g n i f i c a n c e   o f   d i f f e r e n c e   a m o n g   t h e   d i f f e r-
ent  formulae  was  tested  by  applying  the  one  way 
a n a l y s i s   o f   v a r i a n c e   A N O V A   t e s t ,   w h i l e   P a i r e d   t -test 
was  employed  to  determine  the  difference  between 
any  two  formulations  using  a  statistical  software 
package  (Statistical  Analysis  System,  SAS  Institute, 
Inc.,  Cary,  NC,  USA).  Differences  between  related 
parameters  were  considered  statistically  significant 
for p-value equal to or less than 0.05. 
Results and Discussion 
Particle size, entrapment efficiency and drug 
loading  
T a b l e   2   p r e s e n t s   t h e   m e a n   p a r t i c l e   s i z e ,   p o l y-
dispersity and entrapment efficiency for all the pre-
pared formulae. The polydispersity index is a meas-
ure of the width of the dispersion of particles. Narrow 
dispersions  comprise  polydispersity  index  values 
b e t w e e n   0 . 1   a n d   0 . 2 .   H e n c e ,   a c c o r d i n g   t o   T a b l e   2 ,   m o s t  
of the dispersions can be labeled as a narrow disperse; 
e x c e p t   F 2   a n d   F 3   p o l y d i s p e r s i t y   i n d e x   w h i c h   w a s  
slightly higher. Generally, the particle size showed  a 
wide range of variability ranging from 258 to 2743.7 
nm depending on the lipid composition, drug to lipid 
ratio, a n d   t h e   c o n c e n t r a t i o n   o f   t h e   s t a b i l i z e r   ( P V A ) .   I t  
i s   c l e a r   t h a t   a   r a t i o   o f   2 : 1   s o y a l i c i t h i n :   D y n a s a n   a n d   a  
high  lipid  ratio  in  the  nanoparticles  are  important 
f a c t o r s   f o r   g e t t i n g   s m a l l e r   p a r t i c l e   s i z e .   T h e   P V A  
concentration  (0.5%)  was  found  to  be  optimum  for 
both types of Dynasan.  
 
Table 2. Entrapment efficiency, particle size and polydis-
persity for each of the prepared formulae 
Formulation  % EE  %DL  Particle size 
(nm) 
Polydispersity 













794.2 ± 113  0.046 
F2  28.70  16.75 
 
712.9 ± 138  0.297 
F3  6.32  20.90  258 ± 49  0.277 
F4  45.46  12.13  606.1 ± 63  0.006 
F5  69.09  8.03  943.2 ± 97  0.041 
F6  34.92  15.51  766.3 ± 104  0.064 
F7  32.94  15.91  924.8 ± 68  0.005 
F8  51.08  10.91  402.5 ± 34.5  0.005 
F9  35.91  15.31  1216.7 ± 107  0.005 
F10  49.10  11.29  617.3 ± 54.3  0.005 
F11  26.17  15.59  651.6 ± 51.8  0.005 
F12  53.03  10.51  2743.7 ± 183  0.005 
F13  40.00  13.04  461.9 ± 52.1  0.130 
F14  59.09  9.29  343.0 ± 29  0.005 
F15  35.52  13.89  471.3 ± 38  0.005 
 
 
The  lipid  core  material and  drug  composition 
w e r e   f o u n d   t o   a f f e c t   t h e   e x t e n t   o f   5 -FU entrapment in 
SLNs.  Loading  efficiency  of  5-FU  ranging  from 
6.32-69.09% were also observed at different lipids and 
drug ratios. As shown in Table 2, formulae F5, F8 and 
F10  exhibited  the  highest  entrapment  efficiencies 
among all the prepared formulae containing Dynasan 
114 with values equal to 69.09%, 51.08% and 49.10%, 
respectively. The Dynasan 118 containing formulae 
F14  and  F15  had  entrapment  efficiency  values  of 




drug:total lipid ratio from 1:4 (F15) to 1:8 (F14 formu-
la) was found to have a positive effect on both particle 
size  and  entrapment  efficiency  (i.e.  smaller  particle 
size and higher entrapment efficiency).  
The type of Dynasan showed a little effect on the 
size and entrapment efficiency; however, comparing 
F8 with both F13 and F15 revealed that Dynasan 114 
w a s   s u p e r i o r   t o   D y n a s a n   1 1 8   w h e n   u s e d   w i t h   t h e  
s a m e   c o m p o s i t i o n .   B r i e f l y ,   F 8   c o m p o s e d   o f   d r u g   t o  
lipid at 1:4 ratio and soyalithicin to Dynasan114 at 2:1 
r a t i o   ( s t a b i l i z e d   b y   0 . 5 %   P V A )   i s   c o n s i d e r e d   t h e   o p-
t i m u m   f o r m u l a   f o r   t h e   D y n a s a n   1 1 4   g r o u p   w i t h   r e-
gards to the relatively small particle size (402.5 nm), 
polydispersity  value  of  (0.005),  and  high  encapsula-
tion  efficiency 51%. For the Dynasan 118 group, the 
b e s t   f o r m u l a   w a s   F 1 4   ( c o m p o s e d   o f   d r u g   t o   l i p i d   a t   1 : 8  
ratio  and  soyalithicin  to  Dynasan118  at  2:1  ratio), 
which has particle size of 343 nm with 0.005 polydis-
persity and an encapsulation efficiency of 59.09%. 
Particle morphology 
SEM images of SLNs F14 were presented in Fig. 
1   ( A ,   B ,   C ) .   I t   w a s   c l e a r   f r o m   i m a g e   A   t h a t  5-FU loaded 
SLNs were spherical in shape with rough or irregular 
surfaces  with  the  presence  of  some  particle  aggre-
gates. The presence of aggregates might be attributed 
to a short redispersion time after centrifugation and 
drying at room temperature. The sizes observed from 
SEM  micrographs  were  slightly  higher  than  those 
obtained from particle size analyzer. Micrographs B 
and C showed irregular surfaces  of single particles 
under high magnifications. 
Differential scanning Calorimetry (DSC) 
Thermal behavior of the pure drug, Dynasan 114 
a n d   1 1 8   c o m p a r e d   w i t h   t h e   t h e r m o g r a m s   o f   d i f f e r e n t  
lyophilized SLNs formulae in the range of 25 to 350 ºC 
is shown in Fig.   2 .   T h e   t h e r m o g r a m   o f   t h e   p u r e   5 -FU 
showed a sharp melting endotherm at approximately 
282  ºC  followed  by  decomposition,  which  was  in 
agreement with those reported previously [32, 33]. A 
s l i g h t   s h i f t   t o   t h e   m e l t i n g   p e a k s   o f   5 -F U   t o   2 4 0   ° C   w a s  
only observed i n   t h e   c a s e   o f   F 9   a n d   F 1 5 .   S a m e   o b s e r-
vation was reported with 5-FU in PLGA microspheres 
[ 3 4 ] .   T h e   p u r e   D y n a s a n   1 1 4   t h e r m o g r a m   s h o w e d   a  
characteristic sharp peak at 58 ºC corresponding to the 
m e l t i n g   o f   t h e   l i p i d .   T h i s   p e a k   a p p e a r e d   i n   a l l   t h e r-
mograms of the prepared SLNs formulae confirming 
t h e   s o l i d   c r y s t a l l i n e   s t a t e   o f   t h e   l i p i d   i n s i d e   t h e   p r e-
p a r e d   f o r m u l a e .   N o   c h a n g e   i n   t h e   s h a p e   o f   t h e   D y n a-






Fig.  1. Scanning electron microscopy photomicrographs 
for F14 SLNs: A, a field containing different particle sizes 
using 3,300 X magnification power, B, a field showing two 
single particles using 45,000 X magnification power, and C, a 










   
 
 
Fig. 2. DSC thermograms for some selected SLNs formulae containing 5-FU. 
 
 
Fourier transform infrared spectroscopy (FTIR) 
F T I R   s p e c t r a   o f   5 -F U   s h o w e d   a   c h a r a c t e r i s t i c  
peak  in  the  region  3000-2900  cm−1;  represents  C-H 
stretching.  The  5-FU  showed  bands  in  the  region 
1429-1660 cm−1 c o r r e s p o n d i n g   t o   t h e   C =   N   a n d   C   = C  
ring  stretching  vibrations.  The  bands  at  about  1348 
cm−1 w e r e   v i b r a t i o n   o f   t h e   p y r i m i d i n e   c o m p o u n d .   T h e  
absorption bands at 1180  cm−1  and 1246 cm−1  were 




Significant changes were observed in the spectra of 
f o r m u l a t i o n s   a s   w a s   i l l u s t r a t e d   i n   F i g .   3 .   A l l   t h e   c h a-
racteristic absorption  bands  of 5-FU diminished sig-
nificantly  in  the  fi n g e r   p r i n t   r e g i o n   o f   d r u g ,   w h i c h  
revealed that the encapsulated drug inside the lipid 
core  material  existed  in  an  amorphous  state  [37]. 
However, sharp peaks near 2900 and 2800 and 1750 
cm−1 were observed in all formulations due to pres-
ence of Dynasan. These changes could be related to 
those observed by DSC. 
 
 
Fig. 3. FT-IR spectra of some selected SLNs formulae containing 5-FU. 
 
In vitro release 
The  in  vitro  drug  release  profiles  (phosphate 
buffer pH 6.8 at 37 ºC) of entrapped 5-F U   f r o m   t h e  
best four SLNs formulations (F5, F8, F10, and F14), 
w i t h   r e g a r d   t o   s m a l l   p a r t i c l e   s i z e   a n d   r e l a t i v e l y   h i g h  
entrapment  efficiency,  were  presented  in  Fig.  4.  F5 
a n d   F 1 0   w e r e   i n c l u d e d   i n   t h i s   p a r t   s i n c e   t h e y   both 
showed relatively high entrapment efficiencies and a 
s u b m i c r o n   p a r t i c l e   s i z e .   A l l   t h e   f o r m u l a e   s h o w e d   a  
burst drug release with values around 30% cumula-
tive  drug  released.  A  significant  difference  in  the 
c u m u l a t i v e   %   r e l e a s e d   f r o m   F 5   w a s   f o u n d   i n   c o m-
pa r i s o n   w i t h   e a c h   o f   t h e   t h r e e   o t h e r   f o r m u l a e   a t   a l l  
time points, while the difference among F8, F10, and 
F 1 4   w a s   i n s i g n i f i c a n t   u s i n g   o n e   w a y   A N O V A   t e s t .  
T h i s   m a y   b e   a t t r i b u t e d   t o   t h e   aqueous solubility of 
5-FU (12.5 mg/ml) leading to a rapid dissolution of 
d r u g   m o l e c u l e s   p r e s e n t   i n   t h e   s u r f a c e   l a y e r   o f   t h e  
particles. Then, the release rate became slow after the 




5-FU  released  after  48  hours  from  all  formulations 
was less than 70% in all formulations. F5 showed the 
h i g h e s t   m a g n i t u d e   o f   b u r s t   e f f e c t ;   t h i s   m a y   b e   d u e   i t s  
low ratio of soyalecithin. This biphasic drug release 
p a t t e r n   i s   v e r y   c o m m o n   w i t h   S L N s   a n d   w a s   r e p o r t e d  
by many researchers [38, 39]. Recently, Rahman et al. 
[40] studied compositional variations and the interac-
tion  of  the  solid  lipid  nanoparticles  formulation  of 
risperidone  using  a  response  surface  methodology. 
T h e y   f o u n d   t h a t   a   b u r s t   e f f e c t   i n   t h e   r a n g e   o f   2 0 -30% 
appeared according to the variation in the composi-
t i o n .   L i u   e t   a l .   [ 3 9 ]   f o u n d   that insulin release from 
S L N s   p r e p a r e d   b y   s o d i u m   c h o-
late-phosphatidylcholine  based  mixed  micelles  fol-
lowed the same biphasic pattern as it is difficult to 
encapsulate it into hydrophobic polymers. However, 
there is a clear difference in the release rate. The slow 
r e l e a s e   o f   t h e   5 -FU from all formulations suggested a 
homogeneous entrapment of the drug throughout the 
systems. 
Release profile in rat caecal content 
T h e   v a l i d a t e d   H P L C   m e t h o d   u s e d   f o r   t h e   d e-
termination  of  5-FU in rat caecal medium was suc-
cessful i n   s e p a r a t i o n   o f   t h e   d r u g   f r o m   m a j o r   a n d   m i-
nor degradation products. It showed a high linearity 
o f   t h e   s t a n d a r d   c a l i b r a t i o n   c u r v e   o f   5 -F U   i n   t h e   r a t  
c a e c a l   c o n t e n t   w i t h   a   R 2 value of 0.998 in the concen-
tration range from 0.5 to 5 µg/ml [31]. 
F8, 10 and F14   w e r e   c h o s e n   f o r   t h i s   s t u d y   b e-
cause they showed reasonable slow release profile in 
p h o s p h a t e   b u f f e r   p H   6 . 8 ,   i n   a d d i t i o n   t o   t h e i r   c o m-
bined small particle sizes and relatively high entrap-
ment efficiencies. Fig. 5, represents the release profile 
of 5-F U   i n   m edium containing rat caecal contents for 
F 8 ,   F 1 0   a n d   F 1 4 .   G e n e r a l l y ,   t h e   r e l e a s e   p r o f i l e s   f r o m  
the  three  formulae  were  similar  with  no  significant 
d i f f e r e n c e   ( p   ≤   0 . 0 5 ) .   A l l   o f   t h e m   e x h i b i t e d   a   s l o w   r e-
lease profile with diminishing rate. After three hours 
incubation, 26.54% ± 4.75, 28.64 ± 7.52 and 31.33% ± 
4 . 2 7   o f   t h e   d r u g   w e r e   r e l e a s e d   f r o m   F 8 ,   F 1 0   a n d   F 1 4 ,  
r e s p e c t i v e l y ,   w h i l e   o n l y   a r o u n d   8   t o   1 2 %   w e r e   r e-
leased from the three formulae during the next three 
consecutive  hours  (up  to  six  hours).  The  next  three 
hours witnessed only 4-7 %   i n c r e a s e   i n   t h e   c u m u l a t i v e  
a m o u n t   r e l e a s e d .   I n c o m p l e t e   d r u g   r e l e a s e   w a s   n o-
t i c e d   i n   t h e   t h r e e   f o r m u l a e   w i t h   5 1 . 7 7 % ,   4 9 . 5 8 %   a n d  
56.6% maximum cumulative percentage released for 
F8, F10 and F14, respectively, after 24 hours incuba-
t i o n   i n   r a t   c a e c a l   s u s p e n s i o n .   T h e   s l o w   r e l e a s e   p r o f i l e  
e x h i b i t e d   b y   t h e   d r u g   m a y   b e   a s c r i b e d   b y   t h e   l o w e r  
solubility of 5-FU (0.1M ) in neutral phosphate buffers 
[ 4 1 ] .   T h e   h i g h   s t a b i l i t y   o f   5 -FU in rat caecal content 
m e d i u m   w a s   r e p o r t e d   i n   a   p r e v i o u s   s t u d y [31]. Paha-
r i a   e t   a l .   [ 4 2 ]   s t u d i e d   t h e   r e l e a s e   o f   5 -F U   f r o m   E u d r a-
git-c o a t e d   p e c t i n   m i c r o s p h e r e s   i n   a   s i m u l a t e d   c o l o n i c  
medium  containing  rat  caecal  contents  under  anae-
r o b i c   c o n d i t i o n s .   T h e y   r e p o r t e d   a   r e l e a s e   o f   7 0 -80% 
within 8 hours depending on the formulation. Yassin 
e t   a l .   [ 3 0 ]   r e p o r t e d   t h a t   t h e   r e l e a s e   p r o f i l e   o f   5 -F U   f r o m  
chitosan  compression-coated  tablet  incubated  in  rat 









Fig. 5. The release profile of 5-FU from two SLNs formulae F8, F10, and F14 in phosphate buffer saline containing 3% rat 
caecal contents under anaerobic conditions. 
 
The exhibited slow release of 5-F U   f r o m   S L Ns 
formulae  is  not  considered  a  shortcoming  since  the 
u p t a k e   o f   S L N s   i n t o   t h e   t u m o r   t i s s u e   i s   e x p e c t e d   b y   a  
unique phenomenon of solid tumors called Enhanced 
Permeation and Retention (EPR) related to their ana-
tomical  and  pathophysiological  differences  from 
normal tissues. Angiogensis results in the incomplete 
t u m o r   v a s c u l a t u r e   a n d   l e a k y   v e s s e l s   w i t h   g a p   s i z e s   o f  
1 0 0   n m   t o   2   μ m   d e p e n d i n g   u p o n   t h e   t u m o r   t y p e   [ 4 3 ] .  
T h e   l a c k   o f   a   w e l l -defined lymphatic system would 
a l l o w   t h e   t u m o r   d i f f u s e d   S L N s   t o   b e   r e t a i n e d   f or long 
p e r i o d   t i l l   c o m p l e t e   r e l e a s e   o f   t h e   e n t r a p p e d   d r u g  
with a possible higher cellular uptake.  
I n c u b a t i o n   i n   r a t   c a e c a l   c o n t e n t s   i s   c o n s i d e r e d   a  
standard method for the assessment of the specificity 
of  c o l o n i c   m i c r o   f l o r a   a c t i v a t e d   s y s t e m s   d u e   t o   t h e  
high similarity to human as they harbour bifidobac-
terium, bacteroids, and lactobacilli [44-48]. There are 
about 400 distinct bacteria species resident in the co-
lon [49]. Most of the isolated bacteria are anaerobes 
and bacteroids [49-50]. Colonic bacteria play a signif-
i c a n t   r o l e   i n   c o l o n i c   d r u g   d e l i v e r y   s y s t e m   b y   p r o d u c-
ing enzymes and secretatory products that carry out 
several metabolic reactions such as hydrolysis, reduc-
tion, delalkylation, deamination and decarboxylation. 
The maintenance of anaerobic condi t i o n s   i s   v e r y   c r i t-
ical for the activity of the colonic microflora. The most 
c o m m o n l y   u s e d   m e t h o d s   f o r   t h e   a s s e s s m e n t   o f   c o l o n i c  
d e l i v e r y   s y s t e m s   a r e   r a t   c a e c a l   c o n t e n t   a n d   batch 
fermentation. Both methods maintain anaerobic con-
ditions required for the vita l i t y   o f   t h e   b a c t e r i a   a l l o w-
ing for better simulation to the in vivo conditions. 
E a c h   o f   F 8 ,   F 1 0   o r   F 1 4   c a n   b e   i n c o r p o r a t e d   i n   a  
colonic site-s p e c i f i c   s y s t e m   t h a t   a l l o w s   t h e   r e l e a s e   o f  
t h e   f o r m u l a   i n s i d e   t h e   c o l o n .   O n e   s u i t a b l e   s y s t e m   i s  
composed  of  a  hard  gelatin  capsule,  in  which  the 
f o r m u l a   w i l l   b e   f i l l e d   a n d   c o a t e d   w i t h   a  
pH-dependant polymer such as Eudragit S. 
In summary, three SLNs formulae (F8, F10 and 
F14) have been successfully prepared using a simple 
double emulsion procedure that offers a better flex-
ibility and least process related stress on the encap-
sulated drug. These formulae represent a platform for 
t h e   p r e p a r a t i o n   o f   S L N s   f o r   w a t e r   s o l u b l e   a n t i c a n c e r  
d r u g s   i n c l u d i n g   p e p t i d e s .   T h e   S L N s   s y s t e m   h a s   a   h i g h  
potential  to improve  the  uptake  of anticancer drugs 
i n s i d e   c o l o n   t u m o r s .   T h e   r e l e a s e   p r o f i l e   o f   t h e   d r u g   i n  
s i m u l a t e d   c o l o n i c   m e d i u m   s h o w e d   a   p r o l o n g e d   p a t-
t e r n   t h a t   m a y   a l l o w   s p r e a d i n g   o f   t h e   d r u g   i n s i d e   t h e  
colon to cover most of the colonic area wherever the 
t u m o r s   m a y   e x i s t .   T h e   i n c o r p o r a t i o n   o f   t h e s e   f o r m u l a e  
inside colon site-specific delivery capsule is currently 
p r o g r e s s i n g   i n   o u r   l a b   a n d   t h e   e v a l u a t i o n   o f   t h e   i n  
vivo  performance  in  colon  cancer  bearing  animal 
model will be explored in future. 
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